Key Points
- Geron EVP Timothy Williams bought 12,000 shares at $0.94 each, an $11,280 transaction; after the purchase, he directly owned 12,000 shares.
- Geron shares opened at $0.94, near their one-year low of $0.84 and below their 50-day ($1.17) and 200-day ($1.40) moving averages.
- Analysts’ consensus rating is Hold, with an average price target of $3.75; three analysts rate the stock Buy, two Hold, and one Sell.
Geron Corporation (NASDAQ:GERN - Get Free Report) EVP Timothy Williams purchased 12,000 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was bought at an average price of $0.94 per share, with a total value of $11,280.00. Following the transaction, the executive vice president directly owned 12,000 shares in the company, valued at $11,280. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Geron Price Performance
NASDAQ GERN opened at $0.94 on Tuesday. The stock's 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.40. The company has a current ratio of 6.31, a quick ratio of 4.61 and a debt-to-equity ratio of 0.53. The company has a market cap of $606.81 million, a PE ratio of -11.77 and a beta of 0.62. Geron Corporation has a 1 year low of $0.84 and a 1 year high of $2.01.
Institutional Investors Weigh In On Geron
Hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. grew its stake in Geron by 20.5% during the 1st quarter. Principal Financial Group Inc. now owns 39,519 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 6,713 shares in the last quarter. Sei Investments Co. boosted its holdings in shares of Geron by 23.0% during the first quarter. Sei Investments Co. now owns 41,891 shares of the biopharmaceutical company's stock worth $62,000 after purchasing an additional 7,840 shares during the period. Nvest Financial LLC boosted its holdings in shares of Geron by 1.7% during the second quarter. Nvest Financial LLC now owns 517,150 shares of the biopharmaceutical company's stock worth $662,000 after purchasing an additional 8,676 shares during the period. GTS Securities LLC grew its position in Geron by 71.6% during the second quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 9,921 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Geron by 14.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 117,226 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 15,128 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Wedbush dropped their target price on shares of Geron to $5.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 28th. Weiss Ratings upgraded shares of Geron from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Finally, Needham & Company LLC reduced their price target on shares of Geron from $4.00 to $2.50 and set a "buy" rating for the company in a research report on Wednesday, October 28th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $3.75.
Read Our Latest Research Report on GERN
About Geron
(
Get Free Report)
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].